Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer; Fabrice Barlési; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M. Gadgeel; Toyoaki Hida; Dariusz M. Kowalski; Manuel Cobo; Diego Cortinovis; Joseph W. Leach; Jonathan Polikoff; Carlos H. Barrios; Fairooz F. Kabbinavar; Osvaldo Arén Frontera; Filippo de Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S. Chen; Alan Sandler; David R. Gandara

doi:10.1016/s0140-6736(16)32517-x

Keywords

MedicineAtezolizumabDocetaxelInternal medicineOncologyLung cancerPopulationCancerPembrolizumabImmunologyImmunotherapy

Affiliated Institutions

Related Publications

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West , Michael McCleod , Maen Hussein +17 more

Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...

2019 The Lancet Oncology 1597 citations

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle , Marwan Fakih , Juanita Lopez +18 more

Tumour mutational burden (TMB) has been retrospectively correlated with response to immune checkpoint blockade. We prospectively explored the association of high tissue TMB (tTM...

2020 The Lancet Oncology 2300 citations

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen , Denis Soulières , Christophe Le Tourneau +97 more

There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageabl...

2018 The Lancet 1593 citations

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Junshui Ma , Abby B. Siegel , Ann‐Lii Cheng +56 more

Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in...

2018 The Lancet Oncology 2448 citations

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

Purpose In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platin...

2019 Journal of Clinical Oncology 1616 citations

Publication Info

Year: 2016
Type: article
Volume: 389
Issue: 10066
Pages: 255-265
Citations: 4635
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

4635

OpenAlex

Cite This

APA Style

                            
                                
                                    Achim Rittmeyer, 
                                
                                    Fabrice Barlési, 
                                
                                    Daniel Waterkamp
                                
                                et al.
                            
                            (2016). 
                            Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. 
                            The Lancet
                            , 389
                            (10066)
                            , 255-265.
                            https://doi.org/10.1016/s0140-6736(16)32517-x
                        

Identifiers

DOI: 10.1016/s0140-6736(16)32517-x